Clinic
Rady Children's Hospital San Diego
Rady Children's Hospital San Diego was paid $69.04M by Medicaid between Jan 2018 and Dec 2024, across 495 billing codes. Its largest line is 99283, emergency room visit (moderate) — 12% of everything it billed.
33Billing provider infoRADY CHILDREN'S HOSPITAL SAN DIEGO
SAN DIEGO, CA 92123
SAN DIEGO, CA 92123
33aNPI1710065933assigned 11/02/2006
33bProvider typeClinic/Center
28Total paid$69.04M
24GClaims1,450,694
24DCodes billed495
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in California
Rank by total paid#4 of 504
Median peer was paid$102K
This provider vs. median679×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 185,165 | $11.04M | |
| 2019 | 225,973 | $12.77M | |
| 2020 | 230,699 | $10.72M | |
| 2021 | 216,384 | $7.92M | |
| 2022 | 208,520 | $9.27M | |
| 2023 | 219,478 | $9.04M | |
| 2024incomplete | 164,475 | $8.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 90,944 | 89,392 | $8.19M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 8.5% | 4,720 | 3,600 | $5.84M |
| 0450 | Emergency room services | 8.1% | 73,512 | 70,936 | $5.57M |
| Z7500 | 7.9% | 159,401 | 150,251 | $5.42M | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 6.1% | 100,342 | 94,233 | $4.21M |
| 0113 | 4.7% | 1,738 | 1,711 | $3.28M | |
| 41899 | Unlisted procedure, dentoalveolar structures | 3.9% | 1,498 | 1,455 | $2.70M |
| 0123 | 2.7% | 1,207 | 1,193 | $1.86M | |
| 0510 | 2.0% | 40,799 | 36,534 | $1.41M | |
| 93325 | 1.8% | 9,579 | 9,259 | $1.26M | |
| 99199 | Unlisted special service, procedure or report | 1.5% | 10,228 | 9,370 | $1.00M |
| 90378 | 1.3% | 529 | 489 | $929K |
483 more codes
| 0360 | 1.2% | 7,776 | $836K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.2% | 20,598 | $835K |
| 99284 | Emergency room visit (serious) | 1.2% | 2,389 | $809K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1.2% | 462 | $801K |
| 0710 | 1.1% | 8,170 | $792K | |
| 99285 | Emergency room visit (most serious) | <1% | 847 | $690K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,223 | $666K |
| Z7502 | <1% | 17,327 | $661K | |
| J0475 | Injection, baclofen, 10 mg | <1% | 639 | $619K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,924 | $600K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 3,122 | $573K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 58,180 | $506K |
| 80053 | Comprehensive metabolic panel | <1% | 37,526 | $482K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 16,523 | $439K |
| 0636 | <1% | 1,398 | $428K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,414 | $400K |
| 99499 | <1% | 7,570 | $395K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 13,937 | $384K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,445 | $379K |
| 0760 | <1% | 58,408 | $364K | |
| 0250 | <1% | 5,266 | $345K | |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | <1% | 412 | $344K |
| 93975 | <1% | 2,428 | $342K | |
| 72082 | <1% | 5,504 | $336K | |
| G9012 | Other specified case management service not elsewhere classified | <1% | 661 | $308K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 723 | $303K |
| 0410 | <1% | 914 | $301K | |
| 93320 | <1% | 3,551 | $273K | |
| G0378 | Hospital observation service, per hour | <1% | 7,060 | $269K |
| 0301 | <1% | 1,864 | $261K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,362 | $259K |
| 76770 | <1% | 3,989 | $254K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 22,131 | $254K |
| V5298 | Hearing aid, not otherwise classified | <1% | 185 | $242K |
| 0456 | <1% | 5,190 | $236K | |
| Z5942 | <1% | 1,754 | $224K | |
| 92588 | <1% | 4,066 | $213K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 15,458 | $210K |
| 99221 | <1% | 2,766 | $205K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 10,724 | $199K |
| 95782 | <1% | 273 | $189K | |
| Z4307 | <1% | 3,584 | $184K | |
| 87631 | <1% | 3,071 | $181K | |
| 92700 | <1% | 2,239 | $166K | |
| 92557 | <1% | 2,371 | $162K | |
| 0370 | <1% | 408 | $150K | |
| 73090 | <1% | 5,158 | $149K | |
| J3490 | Unclassified drugs | <1% | 10,664 | $149K |
| 92567 | <1% | 6,699 | $149K | |
| 72170 | <1% | 5,095 | $147K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 2,985 | $144K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,284 | $143K |
| 0258 | <1% | 2,398 | $135K | |
| 0306 | <1% | 1,519 | $134K | |
| X4300 | <1% | 1,322 | $124K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 4,746 | $121K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,259 | $121K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13,302 | $117K |
| 73630 | <1% | 3,954 | $116K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,643 | $111K |
| 0320 | <1% | 1,441 | $110K | |
| 97799 | <1% | 8,000 | $109K | |
| 73610 | <1% | 4,100 | $105K | |
| 92523 | <1% | 1,698 | $105K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 2,663 | $102K |
| 73100 | <1% | 4,163 | $102K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,697 | $100K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,939 | $100K |
| X4304 | <1% | 3,842 | $99K | |
| Z5924 | <1% | 1,622 | $95K | |
| 97750 | <1% | 4,552 | $92K | |
| X4303 | <1% | 1,729 | $91K | |
| 93304 | <1% | 856 | $91K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 606 | $88K |
| 93321 | <1% | 2,063 | $85K | |
| Z5958 | <1% | 449 | $83K | |
| Z7610 | <1% | 5,582 | $81K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,874 | $77K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,513 | $77K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 755 | $77K |
| 0272 | <1% | 2,316 | $74K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,945 | $74K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,779 | $70K |
| 97763 | <1% | 1,900 | $69K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,513 | $68K |
| 0271 | <1% | 2,935 | $68K | |
| 74019 | <1% | 1,994 | $66K | |
| 73590 | <1% | 2,595 | $66K | |
| 97139 | <1% | 10,980 | $66K | |
| 73070 | <1% | 2,453 | $65K | |
| 93226 | <1% | 837 | $64K | |
| 80197 | <1% | 3,504 | $64K | |
| 74018 | <1% | 3,497 | $64K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,316 | $63K |
| Z4308 | <1% | 2,204 | $62K | |
| 73130 | <1% | 2,214 | $62K | |
| 73080 | <1% | 2,031 | $61K | |
| 86140 | <1% | 10,149 | $61K | |
| Z5916 | <1% | 1,362 | $59K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 740 | $59K |
| Z5910 | <1% | 1,547 | $59K | |
| 0402 | <1% | 301 | $58K | |
| 73140 | <1% | 3,339 | $58K | |
| 87799 | <1% | 799 | $58K | |
| 83735 | <1% | 7,531 | $58K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,607 | $58K |
| 94010 | <1% | 3,283 | $57K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,625 | $56K |
| 73110 | <1% | 2,057 | $55K | |
| 0305 | <1% | 1,696 | $54K | |
| 87581 | <1% | 2,854 | $54K | |
| 87486 | <1% | 2,854 | $54K | |
| 77073 | <1% | 1,436 | $52K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 313 | $52K |
| 97802 | <1% | 894 | $50K | |
| 76825 | <1% | 305 | $48K | |
| 93225 | <1% | 836 | $47K | |
| T1014 | Telehealth transmission, per minute, professional services bill separately | <1% | 10,590 | $46K |
| 82728 | <1% | 3,968 | $45K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 145 | $44K |
| 51741 | <1% | 2,206 | $43K | |
| 92521 | <1% | 1,051 | $43K | |
| 0302 | <1% | 1,171 | $42K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,299 | $42K |
| Z5936 | <1% | 568 | $42K | |
| X3920 | <1% | 824 | $41K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 973 | $40K |
| 86003 | <1% | 1,893 | $39K | |
| 92508 | Group treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,436 | $38K |
| 84100 | <1% | 6,963 | $38K | |
| Z4310 | <1% | 3,095 | $37K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 8,049 | $37K |
| 80061 | Lipid panel | <1% | 9,979 | $37K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 97 | $36K |
| 97165 | <1% | 1,705 | $36K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 1,140 | $35K |
| 97010 | <1% | 4,703 | $34K | |
| 76870 | <1% | 650 | $34K | |
| 73620 | <1% | 804 | $33K | |
| Z4311 | <1% | 2,707 | $32K | |
| Z5406 | <1% | 2,613 | $32K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,638 | $31K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 774 | $31K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,605 | $31K |
| 73562 | <1% | 1,152 | $30K | |
| 76827 | <1% | 317 | $29K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,285 | $29K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,754 | $29K |
| Z5914 | <1% | 128 | $28K | |
| 82784 | <1% | 3,516 | $28K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,208 | $28K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,936 | $26K |
| 85652 | <1% | 8,879 | $26K | |
| Z7506 | <1% | 185 | $26K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,514 | $25K |
| 51784 | <1% | 374 | $25K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 439 | $25K |
| 82977 | <1% | 4,373 | $24K | |
| 92582 | <1% | 667 | $24K | |
| 87186 | <1% | 3,562 | $24K | |
| 85027 | <1% | 6,397 | $24K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 864 | $23K |
| 92587 | <1% | 410 | $23K | |
| 73060 | <1% | 135 | $23K | |
| 92579 | <1% | 1,009 | $23K | |
| Z4312 | <1% | 1,881 | $23K | |
| 73000 | <1% | 1,001 | $23K | |
| 87497 | <1% | 370 | $22K | |
| 83690 | <1% | 3,119 | $22K | |
| 77072 | <1% | 1,668 | $22K | |
| 73564 | <1% | 879 | $22K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,741 | $22K |
| 83970 | <1% | 387 | $21K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,326 | $21K |
| 84439 | <1% | 5,215 | $21K | |
| 82570 | <1% | 3,251 | $21K | |
| 51798 | <1% | 1,962 | $21K | |
| 84305 | <1% | 1,070 | $20K | |
| 95819 | <1% | 292 | $20K | |
| 93308 | <1% | 240 | $19K | |
| 83540 | <1% | 3,414 | $19K | |
| 87081 | <1% | 12,917 | $18K | |
| 0206 | <1% | 12 | $18K | |
| 12011 | <1% | 509 | $18K | |
| Z4302 | <1% | 1,144 | $18K | |
| 86480 | <1% | 383 | $18K | |
| 83550 | <1% | 3,067 | $18K | |
| 85045 | <1% | 4,318 | $18K | |
| Z5822 | <1% | 929 | $17K | |
| 64642 | <1% | 1,011 | $17K | |
| 0270 | <1% | 5,382 | $17K | |
| 82947 | <1% | 5,954 | $17K | |
| 0300 | <1% | 104 | $17K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,109 | $17K |
| 25600 | <1% | 1,127 | $17K | |
| X3908 | <1% | 659 | $17K | |
| 84436 | <1% | 3,227 | $17K | |
| V5264 | Ear mold/insert, not disposable, any type | <1% | 337 | $17K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,173 | $17K |
| 99201 | <1% | 657 | $16K | |
| 95874 | <1% | 1,922 | $16K | |
| 87040 | <1% | 1,281 | $16K | |
| 64643 | <1% | 809 | $16K | |
| 81001 | <1% | 6,116 | $16K | |
| 82610 | <1% | 965 | $15K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,429 | $15K |
| 88300 | <1% | 1,574 | $15K | |
| 97803 | <1% | 452 | $15K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,963 | $15K |
| 80076 | <1% | 2,257 | $14K | |
| 76885 | <1% | 172 | $14K | |
| 99218 | <1% | 78 | $13K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 13 | $13K |
| 85610 | <1% | 2,971 | $13K | |
| 73560 | <1% | 464 | $13K | |
| 96409 | <1% | 1,543 | $13K | |
| 83516 | <1% | 1,991 | $13K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 91 | $13K |
| 71045 | Radiologic examination, chest; single view | <1% | 674 | $13K |
| 85730 | <1% | 1,964 | $12K | |
| Z5908 | <1% | 276 | $12K | |
| 86355 | <1% | 1,018 | $12K | |
| 86359 | <1% | 1,020 | $12K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 1,655 | $12K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 277 | $12K |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 228 | $11K |
| 81015 | <1% | 3,155 | $11K | |
| Z7514 | <1% | 193 | $11K | |
| 97116 | <1% | 655 | $11K | |
| 86360 | <1% | 996 | $11K | |
| 99243 | <1% | 361 | $11K | |
| Z5932 | <1% | 287 | $11K | |
| 96415 | <1% | 153 | $11K | |
| 87071 | <1% | 2,615 | $11K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 155 | $11K |
| 86357 | <1% | 980 | $11K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 564 | $10K |
| 84460 | <1% | 6,445 | $10K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 542 | $10K |
| 87046 | <1% | 1,122 | $10K | |
| 0730 | <1% | 84 | $10K | |
| 87496 | <1% | 204 | $9K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 901 | $9K |
| X4542 | <1% | 196 | $9K | |
| 85384 | <1% | 856 | $9K | |
| 82670 | <1% | 229 | $9K | |
| 84156 | <1% | 2,445 | $9K | |
| X3910 | <1% | 545 | $9K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 471 | $9K |
| 99070 | <1% | 836 | $9K | |
| Z5956 | <1% | 326 | $8K | |
| 82785 | <1% | 1,271 | $8K | |
| 81000 | <1% | 2,633 | $8K | |
| 0307 | <1% | 302 | $8K | |
| 84450 | <1% | 5,011 | $8K | |
| 73030 | <1% | 345 | $7K | |
| 73660 | <1% | 429 | $7K | |
| 0761 | <1% | 11,747 | $7K | |
| X4100 | <1% | 147 | $7K | |
| 17110 | <1% | 1,470 | $7K | |
| 81025 | <1% | 2,203 | $7K | |
| 86923 | <1% | 145 | $7K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 219 | $7K |
| 88304 | <1% | 652 | $7K | |
| 12001 | <1% | 242 | $7K | |
| T4534 | Youth sized disposable incontinence product, protective underwear/pull-on, each | <1% | 39 | $6K |
| X4110 | <1% | 272 | $6K | |
| 99460 | <1% | 91 | $6K | |
| 73551 | <1% | 198 | $6K | |
| 64644 | <1% | 41 | $6K | |
| G9920 | Screening performed and negative | <1% | 381 | $6K |
| 25605 | <1% | 159 | $6K | |
| 83615 | <1% | 885 | $6K | |
| 94060 | <1% | 195 | $6K | |
| 83002 | <1% | 716 | $6K | |
| X4500 | <1% | 68 | $6K | |
| 74455 | <1% | 79 | $6K | |
| Z5928 | <1% | 144 | $5K | |
| 87045 | <1% | 1,125 | $5K | |
| 29075 | <1% | 677 | $5K | |
| 87205 | <1% | 1,583 | $5K | |
| 86850 | <1% | 654 | $5K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 61 | $5K |
| 92555 | <1% | 266 | $5K | |
| 83880 | <1% | 211 | $5K | |
| 86225 | <1% | 656 | $5K | |
| J7354 | Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg) | <1% | 13 | $5K |
| 87400 | <1% | 209 | $5K | |
| T4541 | Incontinence product, disposable underpad, large, each | <1% | 170 | $5K |
| V5267 | Hearing aid or assistive listening device/supplies/accessories, not otherwise specified | <1% | 148 | $5K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 69 | $5K |
| 80180 | <1% | 287 | $5K | |
| 82139 | <1% | 190 | $5K | |
| L3260 | Surgical boot/shoe, each | <1% | 96 | $4K |
| 82550 | <1% | 679 | $4K | |
| Z5930 | <1% | 164 | $4K | |
| 82248 | <1% | 1,137 | $4K | |
| 93786 | <1% | 158 | $4K | |
| 99234 | <1% | 90 | $4K | |
| 85007 | <1% | 1,972 | $4K | |
| 87806 | <1% | 319 | $4K | |
| 82247 | <1% | 1,945 | $4K | |
| 72100 | <1% | 160 | $4K | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 571 | $4K |
| Z5906 | <1% | 77 | $4K | |
| 83655 | <1% | 6,911 | $4K | |
| 99462 | <1% | 106 | $4K | |
| 85048 | <1% | 995 | $4K | |
| Z7512 | <1% | 137 | $4K | |
| 99217 | <1% | 113 | $3K | |
| 73600 | <1% | 127 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 478 | $3K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 38 | $3K |
| X4112 | <1% | 219 | $3K | |
| 97161 | <1% | 409 | $3K | |
| 76820 | <1% | 98 | $3K | |
| 86376 | <1% | 249 | $3K | |
| 84478 | <1% | 772 | $3K | |
| 86901 | <1% | 1,021 | $3K | |
| 82465 | <1% | 1,124 | $3K | |
| 95117 | <1% | 213 | $3K | |
| 86900 | <1% | 1,022 | $3K | |
| 83993 | <1% | 400 | $3K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 1,009 | $3K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 246 | $3K |
| 84630 | <1% | 279 | $3K | |
| 83519 | <1% | 162 | $3K | |
| 82043 | <1% | 395 | $3K | |
| 83525 | <1% | 1,049 | $3K | |
| 84145 | <1% | 101 | $3K | |
| 93017 | <1% | 27 | $3K | |
| 86769 | <1% | 174 | $3K | |
| 26720 | <1% | 237 | $3K | |
| 99157 | <1% | 46 | $3K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 64 | $2K |
| 84403 | <1% | 466 | $2K | |
| 96367 | <1% | 51 | $2K | |
| 84446 | <1% | 149 | $2K | |
| 84550 | <1% | 515 | $2K | |
| 83021 | <1% | 357 | $2K | |
| 83001 | <1% | 332 | $2K | |
| E0570 | Nebulizer, with compressor | <1% | 53 | $2K |
| 29425 | <1% | 233 | $2K | |
| 29125 | <1% | 152 | $2K | |
| 94664 | <1% | 176 | $2K | |
| 00000 | <1% | 82 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 31 | $2K |
| 82330 | <1% | 117 | $2K | |
| 76010 | <1% | 54 | $2K | |
| 84484 | <1% | 143 | $2K | |
| X4540 | <1% | 64 | $2K | |
| 86160 | <1% | 56 | $2K | |
| X4532 | <1% | 67 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 254 | $2K |
| 80230 | <1% | 53 | $2K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 13 | $2K |
| 84590 | <1% | 107 | $2K | |
| 80299 | <1% | 80 | $2K | |
| 74230 | <1% | 26 | $2K | |
| 76377 | <1% | 15 | $2K | |
| 94680 | <1% | 29 | $2K | |
| 82565 | <1% | 1,450 | $2K | |
| 86665 | <1% | 110 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 274 | $1K |
| 95115 | <1% | 374 | $1K | |
| 82150 | <1% | 185 | $1K | |
| 96450 | <1% | 423 | $1K | |
| 98960 | <1% | 29 | $1K | |
| 86780 | <1% | 229 | $1K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 28 | $1K |
| 87899 | <1% | 748 | $1K | |
| Z5922 | <1% | 25 | $1K | |
| Z5934 | <1% | 19 | $1K | |
| 29065 | <1% | 193 | $1K | |
| A4927 | Gloves, non-sterile, per 100 | <1% | 182 | $1K |
| 64640 | <1% | 17 | $1K | |
| 51600 | <1% | 78 | $1K | |
| J9260 | Injection, methotrexate sodium, 50 mg | <1% | 733 | $1K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 866 | $1K |
| 84480 | <1% | 101 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 64 | $1K |
| 72070 | <1% | 27 | $997.75 | |
| 71020 | <1% | 102 | $983.87 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 186 | $979.50 |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 354 | $897.75 |
| 24530 | <1% | 15 | $887.93 | |
| 70360 | <1% | 91 | $880.46 | |
| 86800 | <1% | 64 | $862.61 | |
| 82607 | <1% | 164 | $853.66 | |
| Z5968 | <1% | 26 | $849.94 | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 12 | $836.40 |
| 93788 | <1% | 158 | $828.41 | |
| 85379 | <1% | 48 | $799.29 | |
| 94644 | <1% | 51 | $776.95 | |
| Z7508 | <1% | 13 | $760.11 | |
| Z4314 | <1% | 39 | $748.02 | |
| 80074 | <1% | 26 | $741.40 | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 219 | $719.99 |
| 51701 | <1% | 17 | $718.29 | |
| 82803 | <1% | 30 | $691.38 | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 262 | $655.04 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 315 | $647.81 |
| 12002 | <1% | 25 | $632.80 | |
| 86664 | <1% | 109 | $631.28 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 92 | $631.26 |
| Z4301 | <1% | 26 | $626.60 | |
| 99205 | Prolong outpt/office vis | <1% | 13 | $545.85 |
| 95816 | <1% | 12 | $533.17 | |
| 87015 | <1% | 387 | $519.06 | |
| 80069 | <1% | 86 | $514.02 | |
| 82310 | <1% | 94 | $509.32 | |
| 76000 | <1% | 36 | $474.15 | |
| 76536 | <1% | 16 | $470.85 | |
| 82525 | <1% | 39 | $468.67 | |
| 84295 | <1% | 101 | $463.87 | |
| 97014 | <1% | 29 | $445.70 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 44 | $437.69 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 15 | $433.50 |
| V5014 | Repair/modification of a hearing aid | <1% | 28 | $426.40 |
| S9470 | Nutritional counseling, dietitian visit | <1% | 65 | $416.00 |
| 88342 | <1% | 41 | $415.11 | |
| 84702 | <1% | 41 | $395.90 | |
| 77080 | <1% | 14 | $384.58 | |
| 11900 | <1% | 119 | $380.28 | |
| 84132 | <1% | 62 | $377.62 | |
| 92015 | Determination of refractive state | <1% | 817 | $352.42 |
| 72040 | <1% | 13 | $352.04 | |
| 84402 | <1% | 81 | $346.57 | |
| 88108 | <1% | 485 | $344.65 | |
| 89051 | <1% | 499 | $335.69 | |
| 84134 | <1% | 15 | $309.75 | |
| A4335 | Incontinence supply; miscellaneous | <1% | 174 | $308.89 |
| 82105 | <1% | 16 | $298.08 | |
| 84520 | <1% | 815 | $294.15 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 198 | $285.88 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 257 | $285.60 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 14 | $284.76 |
| 86747 | <1% | 13 | $276.90 | |
| T1024 | Evaluation and treatment by an integrated, specialty team contracted to provide coordinated care to multiple or severely handicapped children, per encounter | <1% | 14 | $261.80 |
| 98967 | <1% | 227 | $258.48 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 99 | $255.90 |
| 86628 | <1% | 15 | $251.31 | |
| 99366 | <1% | 149 | $248.97 | |
| 85240 | <1% | 12 | $236.58 | |
| 29450 | <1% | 20 | $229.60 | |
| 87328 | <1% | 148 | $226.46 | |
| A6250 | Skin sealants, protectants, moisturizers, ointments, any type, any size | <1% | 186 | $226.35 |
| 93246 | <1% | 14 | $215.91 | |
| 87338 | <1% | 86 | $215.16 | |
| 85014 | <1% | 76 | $208.88 | |
| 29130 | <1% | 64 | $207.88 | |
| 93356 | <1% | 13 | $207.05 | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 32 | $201.50 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $197.28 |
| 87329 | <1% | 147 | $192.35 | |
| 82945 | <1% | 498 | $162.47 | |
| 87181 | <1% | 148 | $158.36 | |
| 82085 | <1% | 25 | $150.00 | |
| 86038 | <1% | 27 | $149.58 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 14 | $140.78 |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 27 | $140.45 |
| 82746 | <1% | 25 | $139.26 | |
| 82390 | <1% | 12 | $138.00 | |
| 84157 | <1% | 481 | $137.14 | |
| 86308 | <1% | 69 | $127.11 | |
| A0425 | Ground mileage, per statute mile | <1% | 156 | $124.91 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 180 | $122.44 |
| 90686 | <1% | 53 | $115.70 | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 39 | $66.63 |
| 85018 | <1% | 100 | $62.79 | |
| 92060 | <1% | 32 | $58.03 | |
| 82272 | <1% | 13 | $47.23 | |
| 82533 | <1% | 12 | $41.87 | |
| 84681 | <1% | 12 | $39.64 | |
| 74000 | <1% | 27 | $25.00 | |
| 82627 | <1% | 13 | $14.40 | |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | <1% | 17 | $8.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 22 | $0.00 |
| J9250 | Methotrexate sodium, 5 mg | 0% | 14 | $0.00 |
| A0999 | Unlisted ambulance service | 0% | 198 | $0.00 |
| 36591 | 0% | 78 | $0.00 | |
| 0310 | 0% | 12 | $0.00 | |
| T4531 | Pediatric sized disposable incontinence product, protective underwear/pull-on, small/medium size, each | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHESTER, MICHAEL (SR. DIRECTOR, REVENUE CYCLE APPLIC)
| Provider | Location | Paid |
|---|---|---|
| Stephens County Hospital Physician Group LLC | Toccoa, GA | $565K |
| Abc Optometric PC | Hillsboro, OR | $100K |
| Burke Hospital Company | Barnwell, SC | $291.66 |
| Stephens County Hospital Authority | Toccoa, GA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.